https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Upon adding RBV, there was no significant difference in SAEs (RR 1.07, 95% CI 0.77-1.48, I = 10%), nor an impact on SVR-12 (RR 1.00, 95% CI 0.98-1.01, I = 41%). There was no evidence of publication bias for either outcome. Subgroup analysis consistently showed lack of benefit among HCV subgroups. Additionally, NCT01826981 was identified as the main source of heterogeneity in the SVR-12 outcome. Our findings suggest nonsignificant differences in safety and efficacy between SOF-based medication regimens with and without RBV w
Like
Comment
Share
